What's Happening?
Hospitals have been increasing their use of oncology biosimilars, leading to reduced spending on oncology treatments. According to a recent analysis published in JAMA, while hospitals have reduced their acquisition costs for these biosimilars, the reimbursements
from insurers have not decreased at the same rate. This discrepancy has allowed hospitals to claim greater margins. The study, which analyzed data from over 66,000 cancer patients and more than 1,500 hospitals, focused on three biosimilars: bevacizumab, trastuzumab, and rituximab. These biosimilars became more available and cheaper between 2020 and 2024, encouraging hospitals to switch from biologics that lost patent protection. The study found that hospitals' retained margins increased significantly as a result of this switch.
Why It's Important?
The increased use of biosimilars in hospitals represents a significant shift in the healthcare industry, potentially leading to more cost-effective treatment options. However, the study highlights a concern that insurers are not adjusting reimbursements to reflect the lower acquisition costs, allowing hospitals to retain higher margins. This situation raises questions about the efficiency of biosimilar adoption and the role of insurers in negotiating prices. The findings suggest that while hospitals benefit financially, the expected savings from biosimilar adoption are not fully realized by the healthcare system, potentially impacting patients and insurers.
What's Next?
The study's findings may prompt calls for policy interventions to ensure that savings from biosimilar adoption are more evenly distributed across the healthcare system. Insurers may need to reconsider their reimbursement strategies to align more closely with acquisition costs. Additionally, there may be increased pressure on hospitals to pass on savings to patients and insurers. The editorial accompanying the study suggests that more work is needed to ensure efficient biosimilar adoption, potentially leading to further research and policy discussions.
